Cargando…

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Genomic changes observed across treatment may result from either clonal evolution or geographically disparate sampling of heterogeneous tumors. Here we use computational modeling based on analysis of fifteen primary breast tumors and find that apparent clonal change between two tumor samples can fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caswell-Jin, Jennifer L., McNamara, Katherine, Reiter, Johannes G., Sun, Ruping, Hu, Zheng, Ma, Zhicheng, Ding, Jie, Suarez, Carlos J., Tilk, Susanne, Raghavendra, Akshara, Forte, Victoria, Chin, Suet-Feung, Bardwell, Helen, Provenzano, Elena, Caldas, Carlos, Lang, Julie, West, Robert, Tripathy, Debu, Press, Michael F., Curtis, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368565/ https://www.ncbi.nlm.nih.gov/pubmed/30737380 http://dx.doi.org/10.1038/s41467-019-08593-4

Ejemplares similares

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Breast tumor microenvironment structures are associated with genomic features and clinical outcome
por: Danenberg, Esther, et al.
Publicado: (2022)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers
por: Chin, Suet-Feung, et al.
Publicado: (2018)

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
por: Murtaza, Muhammed, et al.
Publicado: (2015)

Calling Sample Mix-Ups in Cancer Population Studies
por: Lynch, Andy G., et al.
Publicado: (2012)

High-resolution array CGH clarifies events occurring on 8p in carcinogenesis
por: Cooke, Susanna L, et al.
Publicado: (2008)

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
por: Garber, Haven R., et al.
Publicado: (2022)

Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice
por: Murthy, Rashmi K., et al.
Publicado: (2020)

Genome-driven integrated classification of breast cancer validated in over 7,500 samples
por: Ali, H Raza, et al.
Publicado: (2014)

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers
por: Callari, Maurizio, et al.
Publicado: (2017)

ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
por: Chien, Christine, et al.
Publicado: (2022)

Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2021)

The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

TOX3 Mutations in Breast Cancer
por: Jones, James Owain, et al.
Publicado: (2013)

Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
por: Meyer, Kerstin B, et al.
Publicado: (2008)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Hurvitz, Sara A., et al.
Publicado: (2020)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2021)

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort
por: Mukherjee, A., et al.
Publicado: (2018)

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients
por: Lee, UnJin, et al.
Publicado: (2013)

Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53‐associated features
por: Benor, Gal, et al.
Publicado: (2020)

Multi-omic machine learning predictor of breast cancer therapy response
por: Sammut, Stephen-John, et al.
Publicado: (2021)

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
por: Severson, Tesa M., et al.
Publicado: (2017)

PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes
por: Git, Anna, et al.
Publicado: (2008)

Impact of Intervention Measures on MRSA Clonal Type and Carriage Site Prevalence
por: Cassone, Marco, et al.
Publicado: (2016)

The pitfalls of platform comparison: DNA copy number array technologies assessed
por: Curtis, Christina, et al.
Publicado: (2009)

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer
por: Ali, H. Raza, et al.
Publicado: (2016)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts
por: Callari, Maurizio, et al.
Publicado: (2018)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome
por: Caswell, Deborah R., et al.
Publicado: (2017)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6vagahc1u8fhas9nv6o4ho9fc0